Conference LibraryGated
Claim · 2025 big pharma in vivo CAR-T acquisitions establish $350M-$2.1B valuation range
2025 年 4 - 5 起 big pharma 在 in vivo cell therapy 空间的收购 / 合作 deal · 估值区间 $350M - $2.1B · 公开 PR anchor (EsoBiotec → AstraZeneca $1B verified) · 其余三家 (Capstan / Interius / Orbital) per OPORD-002 P0 待 verify。该 valuation range 是 SunVax 与客户 / 投资人 conversation 时 anchoring effect 的客观行业 …
- Type
- claim
- Domain
- car-t
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- evidence_grade
- B
- category
- industry_valuation_anchor
- status
- draft
- instance_tag
- sunvax-antibody-2025
- claim_statement
- 2025 年 4 - 5 起 big pharma 在 in vivo cell therapy 空间的收购 / 合作 deal · 估值区间 $350M - $2.1B · 公开 PR anchor (EsoBiotec → AstraZeneca $1B verified) · 其余三家 (Capstan / Interius / Orbital) per OPORD-002 P0 待 verify。该 valuation range 是 SunVax 与客户 / 投资人 conversation 时 anchoring effect 的客观行业 r
- claim_evidence_grade
- B
- supporting_papers
- m622-b5-paper-labiotech-azn-acquisition-001,m622-b5-paper-esobiotec-pr-2024-001
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.